Immtech Pharmaceuticals (fka IMMP)

[stockguard]

Immutep to Present at Upcoming Industry Conferences
Tue February 26, 2019 8:00 AM|GlobeNewswire|About: IMMP

SYDNEY, Australia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (IMMP) (Immutep (PRRUF) or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in various upcoming industry conferences.

The Company will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) and new data relating to its pre-clinical product candidate, IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases, at industry conferences in March 2019.

Conference:
World Immunotherapy Congress USA 2019

Dates: 3-5 March 2019

Venue: Grand Hyatt, San Diego, USA

Presentation Title:
Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

Presenter:
Dr. Frédéric Triebel, CSO and CMO of Immutep


Conference:
14th Congress (CACOX) of ECCO (European Crohn’s and Colitis Organisation)

Dates: 6-9 March 2019

Venue: Bella Center, Copenhagen, Denmark

Presentation Title:
IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases

Presenter:
Mathieu Angin, Phd, Immutep Research Scientist

All presentations will be made available on the Company’s website.

About Immutep

Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the US.

Further information can be found on the Company’s website www.immutep.com or by contacting:

U.S. Investors:
Jay Campbell, Chief Business Officer, Immutep Limited
[phone]; [e-mail]

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
[phone]; [e-mail]

U.S. Media:
Garth Russell, LifeSci Advisors
[phone]; [e-mail]

Source: Immutep Limited 2019 GlobeNewswire, Inc.

https://seekingalpha.com/pr/17424272-immutep-present-upcoming-industry-conferences